Condition

Clinical trials for Alcohol Use Disorder

Active public studies that list Alcohol Use Disorder as a condition.

9active studies

6recruiting now

4countries represented

19largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

Alcohol Use DisorderCondition

Semaglutide, PlaceboTreatment

United States19 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-08-12 · NCT07218354See eligibility →

Recruiting nowPhase 2

Tirzepatide in MetALD

Metabolic Alcohol-associated Liver Disease, Alcohol Use DisorderCondition

Tirzepatide, PlaceboTreatment

United States1 locations

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Sponsor

Updated 2026-08-12 · NCT07046819See eligibility →

Recruiting nowPhase 1

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

Alcohol Use Disorder, Weight LossCondition

Semaglutide 1.0 mgTreatment

United States1 locations

Yale UniversitySponsor

Updated 2026-05-12 · NCT07223983See eligibility →

Recruiting nowPhase 2

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

Alcohol Use Disorder, Alcohol Abuse/DependenceCondition

Tirzepatide, PlaceboTreatment

Denmark2 locations

Anders Fink-Jensen, MD, DMSciSponsor

Updated 2026-02-10 · NCT06939088See eligibility →

Recruiting nowPhase 2

Tirzepatide for Alcohol Use Disorder

Alcohol Use Disorder, Obesity and OverweightCondition

Tirzepatide, Placebo injectionsTreatment

United States1 locations

University of Southern CaliforniaSponsor

Updated 2025-10-14 · NCT06994338See eligibility →

Recruiting nowNot applicable

Nottingham Community Liver Biomarkers Cohort

Chronic Liver Disease, Alcohol Use DisorderCondition

Fibrosis BiomarkersTreatment

United Kingdom1 locations

University of NottinghamSponsor

Updated 2019-02-08 · NCT02037867See eligibility →

Opening soonNot applicable

GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

Adiposity, Fatty LiverCondition

Semaglutide, Weight reduction recommendations (nutritional and exercise)Treatment

Switzerland1 locations

Insel Gruppe AG, University Hospital BernSponsor

Updated 2026-08-19 · NCT06546384See eligibility →

Opening soonPhase 2

Combination Therapy for Alcohol Use Disorder

Alcohol Use DisorderCondition

Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1)Treatment

United States1 locations

Johns Hopkins UniversitySponsor

Updated 2026-07-13 · NCT07249554See eligibility →

Active, not recruitingPhase 2

Semaglutide Therapy for Alcohol Reduction (STAR)

Addiction, Alcohol Use DisorderCondition

Take Control, SemaglutideTreatment

United States1 locations

National Institute on Drug Abuse (NIDA)Sponsor

Updated 2026-09-02 · NCT06015893See eligibility →

Related conditions

Obesity1,102 Obesity & Overweight220 Overweight205 Overweight and Obesity130 Type 2 Diabetes108 Hypertension107

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.